Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aytu BioPharma, Inc. - Common Stock (NQ: AYTU )

1.640 -0.050 (-2.96%)
Streaming Delayed Price Updated: 3:59 PM EST, Jan 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aytu BioPharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Aytu BioPharma Reports Third Quarter of Fiscal Year 2023 Financial Results
Via ACCESSWIRE
A Preview Of Aytu BioPharma's Earnings
Via Benzinga
Aytu BioPharma to Report Third Quarter Fiscal 2023 Financial Results on May 11, 2023
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why BlackBerry Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket
Gainers Leju Holdings Limited (NYSE: LEJU) gained 103.7% to $7.25 in pre-market trading after jumping around 97% on Monday . 
Via Benzinga
Aytu BioPharma Announces Approval of Adzenys XR-ODT(R)Manufacturing Site Transfer
Via ACCESSWIRE
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday! 
Via InvestorPlace
Aytu BioPharma Subleases a Portion of Its Manufacturing Facility
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Aytu BioPharma's Return On Capital Employed Insights
Via Benzinga
Aytu BioPharma Reports Second Quarter of Fiscal Year 2023
Via ACCESSWIRE
Earnings Preview For Aytu BioPharma
Via Benzinga
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Second Year in a Row
Via ACCESSWIRE
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 21, 2023
Via ACCESSWIRE
Aytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results
Via ACCESSWIRE
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 14, 2023
Via ACCESSWIRE
Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance
Via ACCESSWIRE
Aytu BioPharma to Present at Lytham Partners Investor Select Conference on January 31
Via ACCESSWIRE
Earnings Scheduled For February 14, 2023
Companies Reporting Before The Bell • WESCO International (NYSE:WCC) is projected to report quarterly earnings at $3.79 per share on revenue of $5.37 billion. 
Via Benzinga
Aytu BioPharma, Inc Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication that is Bioequivalent to Adderall XR(R) for ADHD Patients
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Aytu BioPharma Announces 1-for-20 Reverse Stock Split
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Muscle Maker And 2 Other Stocks Under $1 Insiders Are Aggressively Buying
The Dow Jones settled higher by more than 500 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or... 
Via Benzinga
Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT(R) Prescriptions Generated Since Inception of RxConnect
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Aytu BioPharma Receives a 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.